This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

Browse

Arimistane

Limited Research

Androsta-3,5-diene-7,17-dione (AI dione, "Andro-AI") — steroidal "suicide" aromatase inhibitor sold OTC as a designer supplement; mechanistically related to exemestane but with no published RCT evidence base.

Aliases (11)

androsta-3 · 5-diene-7 · 17-dione · AI dione · Andro-AI · Andros 3 · 5-diene-7 · 17-dione · Arimistane HCl · 7-keto-DHEA metabolite · ATD (loose community shorthand)

TYPICAL DOSE

25-75 mg/day

Daily, oral

ROUTE

Oral (capsule or liquid)

Oral capsule or liquid (with food)

CYCLE

4-12 weeks

4-12 weeks (cycle-adjunct context); not chronic

STORAGE

Room temp; original container; protect from lig…

Room temp

Overview

What is Arimistane?

Arimistane (androsta-3,5-diene-7,17-dione, also called AI dione or 'Andro-AI') is a steroidal mechanism-based ('suicide') aromatase inhibitor sold over-the-counter as a 'designer supplement' / pro-hormone-adjacent product. Mechanistically in the same class as the FDA-approved drug exemestane (Aromasin), arimistane permanently inactivates aromatase enzyme molecules at the active site rather than reversibly competing for binding (anastrozole, letrozole). Not FDA-approved as a drug; sold under DSHEA cover as a dietary supplement. WADA-prohibited under S4.1 Aromatase Inhibitors — banned at all times for both male and female athletes (added to the WADA list in 2017). Notably also produces metabolites that can trigger false-positive boldenone (Equipoise) doping tests.

Key Benefits

When used in a high-E2 context (AAS cycle on aromatizing compounds, TRT-induced symptomatic high E2), arimistane lowers circulating estradiol via permanent aromatase inactivation — reducing water retention, gynecomastia tenderness, and other high-E2 symptoms. Suicide-inhibitor mechanism means each dose contributes to durable suppression. The community use case is cycle-adjunct estrogen control and PCT estrogen rebound management. The secondary 'natty cortisol-control / LH-bumping testosterone booster' supplement claim is folklore-tier with weak supporting data.

Mechanism of Action

Steroidal mechanism-based aromatase inhibitor of the exemestane class. Binds the CYP19A1 active site, is processed as a substrate analog → reactive intermediate covalently attaches to the enzyme → permanent inactivation of that aromatase molecule. Recovery of aromatase activity requires de novo enzyme synthesis (days to weeks), so pharmacodynamic duration outlasts plasma half-life. Unlike anastrozole (reversible / competitive) or letrozole (reversible / very potent), arimistane and exemestane are 'one-and-done' at the enzyme level. Crucial caveat: unlike pharma-grade exemestane (RCT-validated, characterized PK, FDA-approved), arimistane has essentially no published human RCT data, no characterized PK, uncertain half-life, and supplement-grade quality control.

Pharmacokinetics

PeakHalf-life

Approximate curve — visual aid only, not data-precise PK

Research Indications

Most Effective

Crucially: arimistane (or rather a metabolite) is reported to potentially produce a positive WADA test for boldenone (Equipoise) due to shared metabolite signatures (PMID 19089863-class assay literature)

relevant for any tested athlete and a substantive doping-control complication

Research Protocols

Disclaimer: These are commonly discussed research protocols and not medical advice.

Goal

Dose

Frequency

Solo Use

Cycle

Goal:Common cycle-adjunct dose: 25-75 mg/day for 4-12 weeks

Dose:25 mg/day

Frequency:—

Solo:—

Cycle:—

Goal:Not recommended for the user's archetype

Dose:—

Frequency:—

Solo:—

Cycle:—

Goal:Do NOT use arimistane "just to lower cortisol"

Dose:—

Frequency:—

Solo:—

Cycle:—

Goal:Do NOT use as a "natural T booster" in a young eugonadal male

Dose:—

Frequency:—

Solo:—

Cycle:—

Goal:Do NOT stack with anastrozole, letrozole, or exemestane

Dose:—

Frequency:—

Solo:—

Cycle:—

Goal:Do NOT assume supplement-grade dosing is precise

Dose:50 mg labeled may be 30 mg or 80 mg actual

Frequency:—

Solo:—

Cycle:—

Goal:Do NOT use within 6 months of a sanctioned drug-tested competition

Dose:—

Frequency:—

Solo:—

Cycle:—

Goal:Do NOT exceed 75 mg/day

Dose:—

Frequency:—

Solo:—

Cycle:—

Peptide Interactions

Cycle-adjunct context:

Synergistic

Used alongside aromatizing AAS (testosterone, dianabol, anadrol) to manage E2 elevation. Same logic as anastrozole/exemestane in this role — arimistane is th…

HCG (during cycle):

Synergistic

Sometimes co-administered to maintain testicular function; HCG keeps Leydig cells active while AI manages aromatization

TRT (testosterone cypionate / enanthate):

Synergistic

AI is added when TRT-induced E2 climbs symptomatically — but pharma-grade exemestane or anastrozole is a better choice than supplement-grade arimistane for m…

Other aromatase inhibitors (anastrozole, letrozole, exemestane):

Avoid

Redundant; combined AI use can crash E2 to severe-deficiency phenotype. Exemestane in particular is mechanistically identical (suicide AI) — stacking the two…

SERMs (tamoxifen, raloxifene, enclomiphene, clomiphene) without clinical supervision:

Avoid

Combined ER blockade + aromatase blockade can crash tissue-level E2 to severe-deficiency phenotype. Joint pain, bone loss, lipid disruption, mood crash compo…

Heavy alcohol use:

Avoid

Hepatic burden (especially in supplement-category context where contamination cannot be ruled out) + alcohol independently increases aromatase activity (conf…

Other "test booster" supplements claiming AI activity (DAA, fadogia, tongkat, eurycoma):

Avoid

Mechanisms either redundant or not credible in the eugonadal-male context; stacking adds noise without controlled benefit

Estrogen replacement / phytoestrogen-heavy interventions:

Avoid

Mechanism conflict — defeats the purpose of the AI

Statins:

Avoid

Lipid disruption from AI compounds with statin context — coordinate with prescriber if used together (rare in 20yo population)

Most non-hormonal nootropics in the canonical stack:

Compatible

Modafinil, citicoline, NAC, magnesium, fish oil, theanine, rhodiola, curcumin, beta-alanine, creatine — no obvious PD/PK conflict

Caffeine:

Compatible

No expected interaction

Bromantane, Adamax/Semax, Selank:

Compatible

No PK conflict; PD non-overlapping

Quality Indicators

✓

Third-party COA from independent lab (Janoshik, AnaboLab)

Verifies identity (androsta-3,5-diene-7,17-dione), potency (label-claimed mg per dose), and absence of common designer-supplement adulterants (other AIs, pro-hormones, prohibited steroids). Best available QC signal in the absence of FDA oversight.

✓

Vendor with documented batch testing history

Some research-chem vendors publish per-batch HPLC + mass-spec results. Track record matters more here than in pharma-grade categories because there is no FDA backstop.

Generic supplement bottle without third-party assay

Designer-supplement category has had documented historical issues with mislabeling, undisclosed ingredients, and dose inaccuracy. Without independent assay, identity and potency cannot be verified.

✗

Suspiciously cheap product / no manufacturer transparency

Designer-supplement category is associated with adulterant + contamination risks. Unbranded products or those without clear manufacturer / sourcing chain should be avoided.

✗

Claims of identical effect to pharma-grade Aromasin

While the mechanism class is shared with exemestane, no head-to-head data supports the 'identical effect' claim. Vendor copy that overstates equivalence is a quality-of-information red flag for the brand.

What to Expect

Week 1
Tolerability and dose-response.
Week 2-4
Early effect window.
Week 4-8
Peak benefit assessment.
Week 8+
Cycle decision point.

Side Effects & Safety 10

Side Effects

1Joint pain / arthralgia / stiffness — signature AI side effect, dose-dependent, indistinguishable from anastrozole/exemestane class profile
2Reduced libido — at higher doses or with E2 crash
3Dry skin, mucosal dryness
4Lipid disruption (LDL up, HDL down) — predicted from class mechanism, no published arimistane-specific data
5Hair shedding / accelerated androgenic alopecia — possible (steroidal scaffold + androgen-favoring T:E2 shift)
6Erectile dysfunction — E2-crash mediated
7Mood disturbance / irritability / depressed affect — E2-crash mediated
8Sleep disruption
9GI upset (nausea, mild) — reported in some users at higher doses
10Headache

When to Stop

Severe E2 crash syndrome: joint pain + libido loss + mood crash + lipid disruption + bone density loss — same iatrogenic injury seen with all AIs in male off-label use
Bone density loss — silent, detectable only on DEXA; mechanism is the same as anastrozole/exemestane (E2 is the dominant BMD-driving sex steroid in men too); arimistane-specific magnitude unstudied
Hepatic strain — designer-supplement category: contamination risk and unverified purity may add hepatic burden beyond the pharmacological mechanism. No specific hepatotoxicity signal for clean arimistane in published reports, but supplement-category caution applies.
WADA doping-test failures: beyond the obvious AI ban (S4.1), arimistane metabolites have been shown to produce positive boldenone (Equipoise) signals in some assays (PMID 19089863) — a tested athlete using arimistane risks both the AI sanction and a false anabolic-steroid sanction
Adulterant / mislabeling risk: designer-supplement category historically has had products containing undisclosed ingredients (other AIs, pro-hormones, prohibited steroids); third-party COA + vendor reputation are the only QC signal available
First 1-2 weeks: Watch for E2-crash signs — joint pain, libido drop, mood change. If using without bloodwork access, this is the entire surveillance plan.
First 4 weeks: If E2 bloodwork available, recheck E2 + lipids.
6+ weeks: Lipid panel + LFTs.
12 weeks+: Reassess continued need; rotate off if no longer indicated.
MMA training load: AI-induced bone density loss + AI-induced arthralgia + AI-induced mood/libido issues all directly harm combat-sport performance
Daily cognitive workload (business + training): Mood/cognitive blunting from low E2 directly impairs the goal of nootropic stack optimization — opposite direction
Joint health for grappling/striking: AI-induced arthralgia in a sport demanding joint integrity = direct sport-performance harm
No upside: no high-E2 phenotype to correct
Net: zero indication, multiple potential harms, supplement-grade QC adds noise — clear SKIP-FOR-NOW

References

Androsta-3,5-diene-7,17-dione — PubChem CID 222553

pubchem.ncbi.nlm.nih.gov

chemistry, structure, identity

Arimistane

Overview

What is Arimistane?

Key Benefits

Mechanism of Action

Pharmacokinetics

Research Indications

Crucially: arimistane (or rather a metabolite) is reported to potentially produce a positive WADA test for boldenone (Equipoise) due to shared metabolite signatures (PMID 19089863-class assay literature)

Research Protocols

Peptide Interactions

Quality Indicators

Third-party COA from independent lab (Janoshik, AnaboLab)

Vendor with documented batch testing history

Generic supplement bottle without third-party assay

Suspiciously cheap product / no manufacturer transparency

Claims of identical effect to pharma-grade Aromasin

What to Expect

Side Effects & Safety 10

Side Effects

When to Stop

References

Androsta-3,5-diene-7,17-dione — PubChem CID 222553

WADA 2026 Prohibited List (S4.1 Aromatase Inhibitors)

USADA Prohibited List Quick Reference

Rasmussen et al. 2009 — Discrimination between endogenous and exogenous origin of urinary boldenone metabolites in athletes (PMID 19089863)

Aromasin (exemestane) FDA prescribing information

TEAM trial — van de Velde et al. 2011 (Lancet)

IES trial — Coombes et al. 2007 (NEJM)

MA.27 trial — Goss et al. 2013 (J Clin Oncol)

Anastrozole research file (this knowledge base, anastrozole.md)

Tamoxifen research file (this knowledge base, tamoxifen.md)

Enclomiphene research file (this knowledge base, enclomiphene.md)

Buzdar 2003 — Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors (Clin Cancer Res, PMID 12576431)

Geisler 2003 — Aromatase inhibitors and the role of estrogens in postmenopausal breast cancer (Clin Cancer Res equivalent)

Leder et al. 2004 — Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels (J Clin Endocrinol Metab, PMID 14764767)

Burnett-Bowie et al. 2009 — Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone (J Clin Endocrinol Metab, PMID 19470629)

Finkelstein et al. 2013 — Gonadal steroids and body composition, strength, and sexual function in men (NEJM)

Russell & Grossmann 2019 — Estradiol as a male hormone (Eur J Endocrinol)

Smith et al. 2008 — Estrogens and the skeleton in men (Curr Osteoporos Rep, PMID 19094753)

FDA — Tainted Sexual Enhancement, Bodybuilding, and Weight Loss Products: Designer Supplement Warning Letters historical archive

Operation Supplement Safety (OPSS, DoD) — Designer Supplement guidance

Rohle et al. 2007 — Effects of eight weeks of an alleged aromatase inhibiting nutritional supplement on body composition and hormonal profiles in lifting-experienced men (Nutr Metab)

Evolutionary.org — Arimistane forum guide

Kimera Chems product listing — arimistane capsules / liquid

Rasmussen / Sten / Hansen 2008-2010 papers on DHEA-related metabolites and steroid-profile interpretation

See something off?

Related compounds